

Filed: October 31, 2019

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC.,  
SAWAI USA, INC., AND  
SAWAI PHARMACEUTICAL CO., LTD.,  
Petitioner,

v.

BIOGEN MA INC.,  
Patent Owner.

---

IPR2018-01403<sup>1</sup>  
Patent No. 8,399,514

---

**PATENT OWNER'S SUR-REPLY**

---

<sup>1</sup> Case IPR2019-00789 has been joined with this proceeding.

**TABLE OF CONTENTS**

	<b>Page(s)</b>
I. Introduction.....	1
II. The Challenged Claims Are Not Obvious.....	4
A. The Prior Art Does Not Teach an Effective Dose Range .....	4
1. Schimrigk 2004 and January 2006 Press Release Do Not Show That 360 mg/day Was Effective to Treat MS (Ground 1).....	5
2. Kappos 2006 Does Not Teach a Range of Effective DMF Doses (Grounds 2-4).....	8
B. A POSA Would Not Have Been Motivated to Target a DMF Dose of 480 mg/day With a Reasonable Expectation of Success (Grounds 1-4).....	9
1. Side Effects and Convenience Considerations Would Not Have Motivated a POSA to Select 480 mg/day.....	9
2. Biogen’s Phase II Data Indicated That a Dose Lower Than 720 mg/day Would Not Be Effective (Grounds 2-4) .....	11
3. Alleged “Obscured” Treatment Effect Does Not Support a Reasonable Expectation of Success (Grounds 2-4) .....	12
C. None of Petitioner’s Additional Arguments Support Its Obviousness Challenge .....	15
1. Psoriasis Dosing Does Not Provide a Reasonable Expectation of Success for MS (Grounds 1-4).....	15
2. WO ’342 Adds Nothing to Kappos 2006 in Ground 3 .....	16
3. Additional Ground 4 References Do Not Support Unpatentability.....	17

III. Biogen’s Claimed Method Exhibited a Significant Unexpected Benefit in Phase III Studies .....17

IV. Biogen’s Other Objective Evidence Demonstrates Patentability.....19

V. The Claims Cannot Be Obvious Over Dr. O’Neill’s Own Work (Exhibits 1007, 1016, and 1046) .....21

VI. Conclusion .....25

**TABLE OF AUTHORITIES**

	<b>Page(s)</b>
<b>Cases</b>	
<i>Coal. for Affordable Drugs LLC v. Acorda Therapeutics, Inc.</i> , IPR2015-01850, Paper 72 (PTAB Mar. 9, 2017).....	22, 24
<i>Argentum Pharm., LLC v. Alcon Research, Ltd.</i> , IPR2017-01053, Paper 52 (PTAB Sept. 20, 2018).....	21
<i>Arthrex, Inc. v. Smith &amp; Nephew, Inc.</i> , No. 2018-2140 (Fed. Cir. Oct. 31, 2019).....	25
<i>FWP IP ApS v. Biogen MA Inc.</i> , 749 F. App'x 969 (Fed. Cir. 2018).....	16
<i>In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Pat.</i> <i>Litig.</i> , 676 F.3d 1063 (Fed. Cir. 2012) .....	18
<i>In re Katz</i> , 687 F.2d 450 (CCPA 1982).....	<i>passim</i>
<i>In re Soni</i> , 54 F.3d 746 (Fed. Cir. 1995) .....	18
<i>In re Spormann</i> , 363 F.2d 444 (CCPA 1966).....	11
<i>Return Mail, Inc. v. U.S. Postal Serv.</i> , 139 S. Ct. 1853 (2019).....	20
<i>Sanofi v. Watson Labs. Inc.</i> , 875 F.3d 636 (Fed. Cir. 2017) .....	14
<i>Star Sci., Inc. v. R.J. Reynolds Tobacco Co.</i> , 655 F.3d 1364 (Fed. Cir. 2011) .....	2
<i>Stratoflex, Inc. v. Aeroquip Corp.</i> , 713 F.2d 1530 (Fed. Cir. 1983) .....	18

*Varian Med. Sys., Inc. v. William Beaumont Hosp.*,  
IPR2016-00160, Paper 82 (PTAB May 4, 2017) .....24

**Federal Statutes**

35 U.S.C. § 102(a) .....2

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.